ArticleJournal of general internal medicine2026
Clinical Effectiveness of Semaglutide for Weight Loss in a Veterans Affairs' Anti-Obesity Pharmacotherapy Clinic.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a growing global health crisis. Clinical trials have found high-dose semaglutide to be a promising medication for weight loss, but real-world effectiveness data is limited.
objectiveIn this study we assessed weight loss outcomes with semaglutide treatment in patients with overweight or obesity who received care in a Veterans Affairs' (VA) weight management clinic.
designWe performed a retrospective review of patients at the Rocky Mountain Regional VA Medical Center who were started on semaglutide between January 1, 2021 and July 31, 2023. Patients included in the analysis were on the medication for the primary goal of weight loss regardless of their diabetes status, and those who were on semaglutide primarily for glycemic control were excluded.
participantsThe study included 201 veterans who were seen in the VA weight management clinic. MAIN MEASURES: Our primary outcome of interest was mean percent weight loss at 12 months. Changes in body mass index (BMI), systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and hemoglobin A1c (HbA1c) were also analyzed. KEY
resultsAt 12 months, the mean (SEM) total and percent weight loss were 11.5 (0.5) kg and 10.0 (0.6) % (p < 0.001 from baseline), respectively. At 12 months, total body weight loss of ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% was achieved in 74%, 50%, 24%, and 12% of patients, respectively. At 12 months there was a reduction in SBP (SEM) of 3.4 (1.5) mmHg (p = 0.029), reduction in HbA1c of 0.32 (0.1) % (p < .001), reduction in TG of 35.8 (11.8) mg/dL (p = .003), and reduction of LDL-C of 12.0 (4) mg/dL (p = 0.004).
conclusionsSemaglutide treatment in a real-world VA weight management clinic setting resulted in significant weight loss and improvements in cardiovascular and metabolic outcomes, highlighting its effectiveness for managing obesity in veterans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.